Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacokinetics
9 evidence topics · 8 sources
Subcutaneous formulation: half-life and time to maximum concentration after single doses
Subcutaneous formulation: phase 1 pharmacokinetic summary in the sponsor presentation
Subcutaneous formulation: predictability of pharmacokinetics in the phase 1 single ascending dose study
Subcutaneous formulation: plasma levels after the last dose and the rationale for monthly dosing
Subcutaneous formulation: half-life cited for every-other-week and monthly maintenance regimens
Subcutaneous formulation: preclinical pharmacokinetics compared with tirzepatide in primates
Oral formulation: plasma exposure in preclinical models
Oral formulation: dose proportionality of exposure in the phase 1 multiple ascending dose study
Oral formulation: bioavailability, half-life, and food effect
No evidence found.
Distribution, metabolism, and elimination pathways
No evidence found.